Overview
KeriMedical was founded in Geneva in 2016 by a group of hand surgeons with a single thesis: a thumb-base joint implant designed from the ground up for the CMC joint, not a repurposed hip mini-prosthesis. Roughly 150 people across functions, with products in 30 countries.
The portfolio is intentionally narrow. Three implant families covering the full thumb-and-finger reconstruction pathway, plus a broader hand and wrist plating line. Not a generalist trauma catalogue.
The flagship Touch® CMC Prosthesis has been continuously CE-marked since 2015. The current EU MDR Class III certificate (notified body 2862) runs to 15 February 2028. Touch® additionally holds US FDA Premarket Approval (P240020, granted 10 July 2025) as the first dual-mobility CMC 1 prosthesis approved in the United States.
Technology focus
KeriMedical is built around four implant lines, each engineered for a specific stage of thumb and finger reconstruction.
Touch® CMC dual-mobility prosthesis. The central design idea is dual mobility, two articulating surfaces inside the implant, which is what drives the very low dislocation rate seen in the published literature (0.5% vs 4.2% on the legacy single-mobility comparator). The system carries 144 size combinations, the widest range on the market for a CMC arthroplasty, so the implant is matched to the patient rather than the other way around.
KeriFlex® finger implants. Silicone-elastomer arthroplasty for MCP and PIP joints, validated to 10 million flexion cycles. Used primarily in rheumatoid and post-traumatic finger arthritis.
KeriFuse® arthrodesis system. Intramedullary fusion using shape-memory nitinol for DIP and IP-thumb fusion.
KeriMedical hand and wrist plating. Broader plating and fixation line sitting behind the three implant families.
Products distributed in Cyprus
Regulatory & manufacturing
| CE certification | Touch® continuously CE-marked since 2015, current MDR certificate valid through 15 February 2028 |
|---|---|
| EU MDR | Class III (Touch®), notified body 2862 |
| GESY (Cyprus) | Touch®, KeriFlex® and KeriFuse® covered (Touch® under an active ZC code) |
| Manufacturing | Geneva, Switzerland |
Clinical evidence
Touch® dual-mobility versus legacy Arpe single-mobility, 0.5% vs 4.2% dislocation (P=0.02).
Prospective cohort of 130 Touch® patients with 96% implant survival at 2 years.
Prospective series of 107 Touch® cases at more than 3-year follow-up, zero dislocations recorded.
GESY in Cyprus
The Touch® CMC Prosthesis is GESY-covered under an active ZC code. A participating Cypriot hand surgeon working at a GESY-contracted hospital can implant Touch® under reimbursement, with the implant cost included in the hospital settlement and zero out-of-pocket cost to the patient.
KeriFlex® and KeriFuse® are also GESY-covered in Cyprus, on the same participating-surgeon and contracted-hospital basis.
Partnership with OrganoGEN
OrganoGEN is the authorized KeriMedical distributor in Cyprus. We hold consignment stock locally and provide full OR-side surgical support for every Touch® implantation. The team sits in theatre with the surgeon for the first cases, runs the implant sizing through the 144 combinations on-site, and stays through closure.
New Touch® surgeons are onboarded through the OrganoGEN CMC Training Pipeline. The pathway combines cadaver-lab work, observation at established European centres, and case proctoring on the first live cases in Cyprus. The same surgeon network then becomes the natural customer for KeriFlex® and KeriFuse® on subsequent cases.
